Related Experiment Videos
A population-based case-control teratologic study of furazidine, a nitrofuran-derivative treatment during pregnancy
A E Czeizel1, M Rockenbauer, H T Sørensen
1Department of Human Genetics and Teratology, National Center for Epidemiology, Budapest, Hungary.
Objective:
To study human teratogenic potential of furazidine treatment during pregnancy.
Design:
Pair analysis of cases with congenital abnormalities and matched population controls.
Setting:
The Hungarian Case-Control Surveillance of Congenital Abnormalities.
Participants:
38,151 pregnant women who had newborn infants without any defects (population control group) and 22,865 pregnant women who had newborns or fetuses with congenital abnormalities between 1980 and 1996.
Results:
In the case group, 157 (0.7%) and in the control group, 254 (0.7%) pregnant women were treated with furazidine. The case-control pair analysis did not indicate a teratogenic potential of furazidine use during the second to third months of gestation, i.e. in the critical period for major congenital abnormalities.
Conclusion:
Treatment with furazidine during pregnancy did not show teratogenic risk to the fetus.